- Home
- FRHC vs QGEN Comparison
FRHC vs QGEN Comparison
Compare FRHC & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRHC | QGEN |
|---|---|---|
| Founded | N/A | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.7B |
| IPO Year | 1996 | 1998 |
Fundamental Metrics
Financial Performance| Metric | FRHC | QGEN |
|---|---|---|
| Price | $147.53 | $42.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $45.76 |
| AVG Volume (30 Days) | 70.1K | ★ 2.4M |
| Earning Date | 06-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 7.17% |
| EPS Growth | ★ 79.29 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $2,191,291,000.00 | N/A |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | N/A | $5.71 |
| P/E Ratio | $281.77 | ★ $24.01 |
| Revenue Growth | ★ 6.86 | N/A |
| 52 Week Low | $107.98 | $32.53 |
| 52 Week High | $181.27 | $57.82 |
Technical Indicators
Market Signals| Indicator | FRHC | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 59.78 |
| Support Level | $146.40 | $42.82 |
| Resistance Level | $150.54 | $44.03 |
| Average True Range (ATR) | 4.62 | 0.86 |
| MACD | -0.80 | -0.00 |
| Stochastic Oscillator | 15.32 | 59.32 |
Price Performance
Historical ComparisonAbout FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with reportable segments into the following four segments: Brokerage, Banking, Insurance, and Other. The majority of revenue is from the Banking segment. Banking segment consists of the operations of Freedom Bank KZ and Freedom Bank TJ. Geographically, operates in Kazakhstan, Armenia, Cyprus, the USA, and others, with maximum revenue from Kazakhstan.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).